September 26, 2019
Noveome Biotherapeutics kicks off phase 1 clinical trial of its ST266 for the optic nerve and brain
Nevome Biotherapeutics has started testing its ST266 when delivered intranasally in a Phase 1 open label clinical trial, in patients diagnosed with intraocular hypertension who have not yet developed optic nerve damage, with topline results expected by end of the second quarter of 2020.